GlassScriptPhysician profile
Babak Hooshmand
NPI 1023380086
$3,677.02
in general payments reported to CMS, 2019-2025
12 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.64 · 2020: $473 · 2021: $781 · 2022: $645 · 2023: $622 · 2024: $636 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,720 · Education: $44.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.53 |
| Education | $44.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $905.71 | 2020-2025 | Rezzayo, Kimyrsa, Vabomere |
| Abbvie INC. | $861.88 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $396.49 | 2020-2025 | Zerbaxa, Dificid, Pifeltro |
| Paratek Pharmaceuticals, INC. | $388.31 | 2020-2025 | Nuzyra |
| Gilead Sciences, INC. | $279.43 | 2020-2024 | |
| Pfizer INC. | $211.85 | 2023-2025 | |
| Astellas Pharma US INC | $176.90 | 2020-2024 | Cresemba |
| Shionogi INC | $161.70 | 2022-2025 | Fetroja |
| Allergan, INC. | $141.36 | 2020 | |
| Ferring Pharmaceuticals INC. | $108.55 | 2024 | Rebyota |
| La Jolla Pharmaceutical Company | $31.20 | 2024 | Xacduro |
| Biomerieux INC | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Hooshmand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.